



(86) Date de dépôt PCT/PCT Filing Date: 2004/03/15
(87) Date publication PCT/PCT Publication Date: 2004/09/30
(45) Date de délivrance/Issue Date: 2011/05/24
(85) Entrée phase nationale/National Entry: 2005/09/13
(86) N° demande PCT/PCT Application No.: IB 2004/000896
(87) N° publication PCT/PCT Publication No.: 2004/082733
(30) Priorité/Priority: 2003/03/17 (FR0303257)


(51) Cl.Int./Int.Cl. *A61M 1/34* (2006.01),
A61L 2/00 (2006.01), *A61M 1/16* (2006.01)

(72) Inventeurs/Inventors:
CHEVALLET, JACQUES, FR;
MERCIER, GUY, FR;
RADA, HIRAM, FR;
MONCHI, MEHRAN, FR

(73) Propriétaire/Owner:
GAMBRO LUNDIA AB, SE

(74) Agent: ROBIC

(54) Titre : DISPOSITIF ET PROCEDE DE TRAITEMENT DE SANG AVEC EXTRACTION SELECTIVE DE SOLUTES
(54) Title: BLOOD TREATMENT DEVICE AND METHOD WITH SELECTIVE SOLUTE EXTRACTION



(57) Abrégé/Abstract:

The object of the present invention is the filtration of blood in order to selectively separate and extract molecules of a given size via extracorporeal systems for separating substances. The invention thus concerns an extracorporeal blood treatment device



(57) **Abrégé(suite)/Abstract(continued):**

including: one or more exchangers (1) comprising a first inlet (2) for the blood to be treated, a first fluid outlet (4) and a second fluid outlet (5), an inlet line (10) for the blood to be treated, connected to the first inlet (2) of the exchanger (1), a blood outlet line (or venous line) (11) coupled to the first outlet (4) of the exchanger (1), one or more treatment units (21) comprising at least a first fluid inlet (22) and at least a first fluid outlet (24), wherein the second outlet (5) of the exchanger (1) is in fluid communication with the first inlet (22) of the treatment unit (21), the invention being characterised in that the first outlet (24) of the treatment unit (21) is in fluid communication with the inlet line (10).

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION
EN MATIÈRE DE BREVETS (PCT)

VERSION RÉVISÉE

(19) Organisation Mondiale de la Propriété
Intellectuelle
Bureau international(43) Date de la publication internationale
30 septembre 2004 (30.09.2004)

PCT

(10) Numéro de publication internationale
WO 2004/082733 A3(51) Classification internationale des brevets⁷ : A61M 1/34,
1/16, A61L 2/00(30) Données relatives à la priorité :
0303257 17 mars 2003 (17.03.2003) FR(21) Numéro de la demande internationale :
PCT/IB2004/000896(71) Déposant (pour tous les États désignés sauf US) : **GAM-
BRO LUNDIA AB** [SE/SE]; Magistratsvägen 16, S-226
43 Lund (SE).

(22) Date de dépôt international : 15 mars 2004 (15.03.2004)

(72) Inventeurs; et

(75) Inventeurs/Déposants (pour US seulement) : **CHEVAL-
LET, Jacques** [FR/FR]; 8, route de Ternay, F-69360
Serezin du Rhone (FR). **MERCIER, Guy** [FR/FR]; 50,
rue de la Marne, F-69500 Bron (FR). **RADA, Hiram**
[FR/FR]; 1, Impasse du Presbytère, F-69008 Lyon (FR).


(25) Langue de dépôt : français

(26) Langue de publication : français

[Suite sur la page suivante]

(54) Title: BLOOD TREATMENT DEVICE AND METHOD WITH SELECTIVE SOLUTE EXTRACTION

(54) Titre : DISPOSITIF ET PROCÉDE DE TRAITEMENT DE SANG AVEC EXTRACTION SELECTIVE DE SOLUTES



(57) **Abstract:** The object of the present invention is the filtration of blood in order to selectively separate and extract molecules of a given size via extracorporeal systems for separating substances. The invention thus concerns an extracorporeal blood treatment device including: one or more exchangers (1) comprising a first inlet (2) for the blood to be treated, a first fluid outlet (4) and a second fluid outlet (5), an inlet line (10) for the blood to be treated, connected to the first inlet (2) of the exchanger (1), a blood outlet line (or venous line) (11) coupled to the first outlet (4) of the exchanger (1), one or more treatment units (21) comprising at least a first fluid inlet (22) and at least a first fluid outlet (24), wherein the second outlet (5) of the exchanger (1) is in fluid communication with the first inlet (22) of the treatment unit (21), the invention being characterised in that the first outlet (24) of the treatment unit (21) is in fluid communication with the inlet line (10).

(57) **Abrégé :** L'objet de la présente invention est la filtration de sang afin de séparer et extraire sélectivement des molécules de taille choisie par le biais de systèmes extracorporels pour la séparation de substances. Ainsi l'invention concerne un dispositif de traitement extracorporel de sang comprenant: au moins un échangeur (1) comportant au moins une première entrée (2) pour le sang à traiter, une première sortie (4)

[Suite sur la page suivante]



WO 2004/082733 A3

WO 2004/082733 A3

MONCHI, Mehran [FR/FR]; 778, Avenue Anatole France, F-77190 Dammarie Les Lys (FR).

OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(74) Mandataire : SUTTO, Luca; Gambro Intellectual Property Department, Hospal International Marketing Management, 61, Avenue Tony Garnier, F-69007 Lyon (FR).

Publiée :

— avec rapport de recherche internationale

(81) États désignés (*sauf indication contraire, pour tout titre de protection nationale disponible*) : AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(88) Date de publication du rapport de recherche internationale:

4 novembre 2004

Date de publication du rapport de recherche internationale révisé:

7 avril 2005

(84) États désignés (*sauf indication contraire, pour tout titre de protection régionale disponible*) : ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), européen (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR),

(15) Renseignements relatifs aux corrections:

voir la Gazette du PCT n° 14/2005 du 7 avril 2005, Section II

Correction précédente:

voir la Gazette du PCT n° 07/2005 du 17 février 2005, Section II

En ce qui concerne les codes à deux lettres et autres abréviations, se référer aux "Notes explicatives relatives aux codes et abréviations" figurant au début de chaque numéro ordinaire de la Gazette du PCT.

de fluide et une deuxième sortie (5) de fluide, une ligne d'entrée (10) du sang à traiter raccordée à la première entrée (2) de l'échangeur (1), une ligne de sortie (ou ligne veineuse) (11) du sang raccordée à la première sortie (4) de l'échangeur (1), au moins une unité de traitement (21) comportant au moins une première entrée (22) de fluide et au moins une première sortie (24) de fluide, la deuxième sortie (5) de l'échangeur (1) étant en communication de fluide avec la première entrée (22) de l'unité de traitement (21), caractérisé en ce que la première sortie (24) de l'unité de traitement (21) est en communication de fluide avec la ligne d'entrée (10).

BLOOD TREATMENT DEVICE AND METHOD WITH SELECTIVE SOLUTE EXTRACTION

Field of the invention

The object of the present invention is a device and a method for the treatment of blood with selective extraction of solutes.

The object of this patent application is the filtration of blood to selectively separate and extract dissolved substances of chosen molecular size by means of extracorporeal systems designed for the separation of substances.

10 Such systems are used for the treatment of blood containing solutes with different molecular weights. Such substances are, for example, urea, of molecular weight 60 daltons, phosphate (96-97 daltons), creatinine (113 daltons), vitamin B₁₂ (1 355 daltons), inulin (5 200 daltons), beta 2-microglobulin (12 000 daltons), and albumin (58 000 daltons).

Are hereafter termed 'small-sized molecules' molecules of molecular mass less than about 2 000 daltons, 'medium-sized molecules' molecules of molecular mass between 2 000 and 50 000 daltons, and 'large-sized molecules' molecules of molecular mass greater than 50 000 daltons (for example, proteins).

State of the art


20 It is known from WO96/28198 a two-stage size separation circuit based on the available filtration technology and dialysis hardware for the treatment of acute renal failure, which is said to be capable of offering high single-pass elimination of the free virus (and boasting a time constant of approx. 10 to 15 minutes for the systemic clearance): such a circuit shows a closed recirculation sub-circuit (see for example figure 2).

1a

At the same time, the circuit depicted in WO96/28198 shows a line, referenced by number 17, which is an inlet line (allowing the liquid to enter into the treatment unit 13): therefore, such a line is not a "discharge line" of the treatment unit.

Such systems are often systems with extracorporeal membranes for the separation of solutes of molecular weight lower than that of albumin, applied to the treatment of renal insufficiency.

Improvements have always been sought in particular to ameliorate clearance, reduce treatment time and to make such systems simpler and less costly. We remind that clearance of a solute is the amount of that solute in a given volume of treated blood.



In the field of dialysis, the first membranes used were highly permeable to small solutes of molecular size up to 200 daltons. The clearance of small solutes depends on the permeability and diffusion capacity of the membrane used.

The lack of permeability of the first membranes for certain medium-sized solutes in the vitamin B₁₂ range (1 355 daltons) was blamed for the occurrence of multiple uraemic neuropathies.

10 To improve the clearance of medium-sized molecules, a first response was to add to the diffusion flow through the membrane a convection flow using high flow membranes with a molecular size cut-off value of 40 000 daltons. The cut-off value of a membrane is defined as the molecular size for which no more than 10 % of the solute travels through the membrane.

However, problems met in embodying this response include difficulty in controlling the ultrafiltration rate obtained by the convection flow, and the high loss of useful plasma constituents such as hormones, vitamins and amino acids.

20 A second response for the improvement of the clearance of medium-sized molecules was haemo-filtration, a purely convective method for the elimination of solutes by the membrane. However, this method extracts a large amount of liquid, therefore requiring a compensatory pre- and (or) post-dilution with sterile liquid, and a membrane that is highly permeable to solutes of molecular size up to 40 000 daltons. However, in a purely convective mode, the clearance depends on the mode of dilution (pre- or post-dilution), the blood flow rate and the infusate flow rate. With conventional haemo-filtration, the clearance of small-sized molecules is poorer than that obtained in haemodialysis mode. The clearance in haemo-filtration mode could reach that of haemodialysis if the infusate flow rate, the blood flow and the membrane area were increased. However, this is impractical, increases treatment cost and results in loss of amino acids and hormones. In addition, the blood flow rate is limited, in particular in patients with poor blood access.

30 Concerning the clearance of small-sized molecules, when it was discovered that this clearance was limited in haemo-filtration mode, the two processes of haemo-filtration and haemodialysis were combined. This simultaneous method was known as haemo-diafiltration. However, problems that arise include difficulty in precisely controlling the haemo-filtration flow, high loss of hormones and amino acids, the complexity of the

system, the large quantities of sterile liquid and dialysate necessary, and consequently the high cost of the treatment.

Thus the use of a single filter working in different operating modes still failed to solve the particular problems of loss of molecules in a certain size range, and of high treatment cost.

A proposal was then made by Drs J.C. Kingswood and F.D.Thompson of a continuous haemo-filtration with no re-injection liquid: the treatment of the ultra-filtrate was performed by a second membrane also working in spontaneous ultrafiltration. Figure 1 represents the dialysis set-up derived from this proposal.

10 The procedure is to treat a first ultra-filtrate, obtained from a first hollow fibre membrane, by sending it through a second hollow fibre membrane in ultrafiltration mode. A first ultrafiltration is performed through a first high-flow membrane impermeable to molecules having mass larger than 10 000 daltons. The apertures in the second membrane are smaller than those in the first.

As shown in Figure 1, at the outlet from the first membrane the unfiltered liquid, mainly containing large-sized molecules, is sent to the patient for re-injection. The first ultra-filtrate containing small- and medium-sized molecules is filtered through the second membrane. The liquid not filtered by the second membrane, mainly containing medium-sized molecules, is collected in a waste bag. The second ultra-filtrate, mainly containing
20 small-sized molecules, is re-injected in post-dilution via the patient's venous line.

This saves consuming excessive amounts of sterile liquid in post-injection, and allows re-injection in the patient of a liquid containing few medium-sized molecules.

Even so, a high loss of nutrients, amino acids, glucose and vitamins occurs, and the clearance of small ions such as potassium is poor.

Accordingly, another dialysis device was designed. It was considered that the uraemic molecules that had to be removed were of molecular mass less than 200 daltons and those between 10 000 and 40 000 daltons.

This consideration gave rise to a device composed of three filters, depicted in Figure 2.

A first filter has a cut-off value of about 40 000 daltons. The blood flows through this first filter to yield a first filtrate containing small-sized and medium-sized molecules, i.e., molecules of molecular mass less than 40 000 daltons. The solutes of mass between 10 000 and 40 000 daltons are then eliminated by ultrafiltration through the second filter, which has a cut-off value below 10 000 daltons. The second filtrate is then treated by haemo-filtration with a membrane with a cut-off value of about 200 daltons. Thus the purified filtrate, containing solutes between 200 and 10 000 daltons, is returned for post-infusion to the patient, who also receives the molecules of molecular mass greater than 40 000 daltons.

10 However, the clearance of all the solutes depends on the ultrafiltration rate in filter 1, which cannot exceed 30 % of the blood flow, a value that is low compared with that attained in conventional haemodialysis. This raises operating costs.

 Lastly, Patent US 6,193,681 describes an apparatus to treat septicaemia in the blood, depicted here in Figure 3. The blood flows first through a UV irradiation device and then through a blood concentrator before re-injection in the patient. A secondary circuit is connected to a second outlet from the blood concentrator from which the fluid flows out through a filter followed by a membrane module and a dilution source, and is then injected upstream of the blood concentrator.

20 There is in addition an analogous problem with plasmapheresis. Therapeutic exchange plasmapheresis is carried out on patients whose plasma contains one or more harmful or toxic substances.

 These solutes are eliminated from the plasma by the same principle as the elimination of solutes from blood, one difference being the greater molecular mass of the solutes to be extracted from the plasma.

 Thus recurrent problems have been encountered in the design of the devices in prior art, namely:

- High consumption of perfusion liquid,
- High losses of nutrients, amino acids, glucose and vitamins,
- Poor clearance of solutes,
- 30 - High cost of devices comprising several filters and pumps.

The problem addressed in this patent application is how to achieve selective elimination of molecules in one or more molecular mass range(s) with good clearance, yet consume very small amounts of sterile liquid.

For example, for patients in a state of septicaemia, many medium-sized molecules have to be eliminated, while still maintaining satisfactory elimination of small-sized molecules. Septicaemia is characterised by abundant repeated release of specific pathogenic germs from an initial point of infection.

10 An auxiliary problem is optimally adapting such a system for long-term therapy carried out in an intensive care environment without a risk of filter clogging. Such an adaptation can be achieved by judicious choice of mode of operation of the various filters, of use and appropriate positioning of means to regulate flow rate, of controlled flow rates and of hydraulic design of the lines.

Description of the invention

According to the present invention, there is provided a device for the extracorporeal treatment of blood comprising:

- at least one exchanger (1) having a semi-permeable membrane (6) dividing said exchanger into a first chamber (7) and a second chamber (8), at least one first inlet (2) for blood to be treated in fluid communication with the first chamber (7), a first fluid outlet (4) in fluid communication with the first chamber (7) and a second fluid outlet (5) in fluid communication with the second chamber (8) of the exchanger (1),
- an input line (10) for blood to be treated connected to the first inlet (2) of the exchanger (1),
- a blood output line (11) connected to the first outlet (4) of the exchanger (1),
- at least one treatment unit (21) comprising a semi-permeable membrane (26), dividing the treatment unit (21) into a first chamber (27) and a second chamber (28), at least one first fluid inlet (22) in fluid communication with the

second chamber (28), and at least one first fluid outlet (24) in fluid communication with the first chamber (27) of the treatment unit (21),

- the second outlet (5) of the exchanger (1) being in fluid communication with the first inlet (22) of the treatment unit (21),

- the first outlet (24) of the treatment unit (21) being in fluid communication with the input line (10),

wherein

- the treatment unit (21) includes a second fluid outlet (25) in fluid communication with the second chamber (28) of the treatment unit (21),

10 - the second outlet (25) of the treatment unit (21) is in fluid communication with a first waste liquid discharge line (30) having a first end and a second end, the first end of said first waste liquid discharge line being connected with the second outlet (25) of the treatment unit (21) and the second end of said first waste liquid discharge being connected to a drain or to a first waste liquid container (31).

Preferably, in order to solve the problem outlined above, the invention provides for an extracorporeal blood treatment device comprising at least one exchanger 1 equipped with at least one first inlet 2 for the blood to be treated, a first fluid outlet 4 and a second fluid outlet 5, an input line 10 for blood to be treated connected to the first inlet 2 of the exchanger 1, a blood output line (or venous line) 11 connected to the first outlet 4 of the exchanger 1, at least one treatment unit 21 comprising at least one first fluid inlet 22 and at least one first fluid outlet 24, the second outlet 5 of the exchanger 1 being in fluid communication with the first inlet 22 of the treatment unit 21, characterized in that the first outlet 24 from the treatment unit 21 is in fluid communication with the input line 10.

Preferably, the invention also concerns an extracorporeal blood treatment method to be implemented by means of the extracorporeal blood treatment device comprising an exchanger 1 to which are connected a blood input line 10 and a

6a

blood output line 11 and a treatment unit 21, which method comprises the following steps: blood is sent through input line 10 connected to exchanger 1, filtered first in the exchanger 1 to produce a first filtrate, which is filtered at least a second time by the treatment unit 21 to produce a second filtrate, which is sent through the input line 10 for pre-dilution of blood to be treated, and the blood is sent from the outlet from exchanger 1 to the output line 11.

Other advantages and characteristic of the invention will be inferred from the following description.

Brief description of the drawings

10 The description refers to the appended drawings, where:

Figure 1 shows the state of the art concerning the use of two filters with different cut-off values and with post-dilution re-injection.

Figure 2 shows the state of the art concerning the use of three filters with different cut-off values and with post-dilution re-injection.

Figure 3 shows the state of the art of Patent US 6,193,681.

Figures 4 to 9 are schematic diagrams of the device for the treatment of physiological fluid according to the invention, together with various embodiments.

Figures 10 and 11 show the estimated results in terms of clearance according to the molecular size of the solutes for two configurations of the device according to the invention.

20

Detailed description


Figure 4 shows the principle of the invention in diagrammatic form: blood inflow through an input line, its arrival in the exchanger and its outflow from the exchanger through an output line, together with the treatment of the first filtrate by a treatment unit and the injection of the liquid leaving the treatment unit in pre-dilution in the arterial line. We can define this concept as a "cascade" of filtration steps with re-injection of the final filtrate in pre-dilution; in detail: a first filtrate is a second time filtrated, and the second filtrate is then injected at the inlet of the first filter, or in "pre-dilution".

6b

Figure 5 shows the extracorporeal blood treatment device of the invention consisting of an exchanger 1 comprising a first inlet 2 for the blood to be treated, a first fluid outlet 4 and a second fluid outlet 5, an input line 10 for the blood to be treated, or arterial line, connected to the first inlet 2 of the exchanger 1, a blood output line, or venous line, 11 connected to the first outlet 4 of the exchanger 1. A treatment unit 21 comprises a first fluid inlet 22, and a first fluid outlet 24; the second fluid outlet 25 of the exchanger 1 is in fluid communication with the first inlet 22 of the treatment unit 21, and the first outlet 24 of the treatment unit 21 is in fluid communication with the input line 10.

The fluid communication between the first inlet 22 of the treatment unit 21 and the second outlet 5 of the exchanger 1 is made by a duct 12.

10



The exchanger 1 can be equipped with a semi-permeable membrane 6 that divides it into a first chamber 7 and a second chamber 8. The first inlet 2 of the exchanger is in fluid communication with the first chamber 7 of the exchanger, the first outlet 4 of the exchanger is in fluid communication with the first chamber 7 of the exchanger, and the second outlet 5 of the exchanger is in fluid communication with the second chamber 8 of the exchanger.

10 The blood input line 10, termed the 'arterial line', connected to the first inlet 2 of the exchanger 1, the blood output line 11 termed the 'venous line', connected to the first outlet 4 of the exchanger and the first chamber 7 of the exchanger form part of an extracorporeal blood treatment circuit.

In one embodiment shown in Figure 6, the exchanger 1 can include a second inlet 3 in fluid communication with the second chamber 8 and in fluid communication with a first source of dialysis liquid 9. In this mode of operation the blood and the dialysis liquid flow in opposite directions in each of the two chambers.

Figure 5 shows the treatment unit 21 equipped with a semi-permeable membrane 26 that divides it into a first chamber 27 and a second chamber 28.

The treatment unit 21 can advantageously have a second fluid outlet 25.

20 Thus the first outlet 24 of the treatment unit 21 is in fluid communication with the first chamber 27 of the treatment unit 21 and the second outlet 25 of the treatment unit 21 is in fluid communication with the second chamber 28 of the treatment unit 21.

Alternatively, the first inlet 22 of the treatment unit 21 can be in fluid communication with either the second chamber 28 of the treatment unit 21, or with the first chamber 27 of the treatment unit 21.

The second outlet 25 of the treatment unit 21 is in fluid communication with a first waste liquid discharge line 30, which discharge line 30 can connect the second outlet 25 of the treatment unit 21 to a drain or to a first waste liquid container 31.

The treatment unit 21 can also have a second inlet 23, which second inlet 23 is in fluid communication with the second chamber 28 and with a second source of dialysis liquid 29. In this operating mode of the treatment unit, shown in Figure 7, the dialysis liquid flows in the opposite direction to the physiological liquid arriving via the first inlet 22.

The exchanger 1 and the treatment unit 21 have different characteristics. The membrane 6 of the exchanger 1 can be a high flow membrane, and the membrane 26 of the treatment unit 21 can be a low flow membrane.

10 A low-flow membrane has low water permeability. The ultrafiltration coefficient is between 2 and 10 ml/h,mmHg,m². A high-flow membrane has a much higher hydraulic permeability. The ultrafiltration coefficient is 20 to 50mL/h,mmHg,m².

The exchanger or the treatment unit may comprise a hollow fiber membrane (called also capillary filter) or a plate fiber membrane, this means with membrane sheets.

Thus the permeability to molecules of the membrane 6 in the exchanger 1 is greater than the permeability to molecules of the membrane 26 in the treatment unit 21, at least above a certain molecular mass.

20 More particularly, we can define a ratio or a difference between the two cut off values of the first membrane and the second membrane. Thus, we can define ratio of the cut-off value of the first membrane to the cut off value of the second membrane less than or equal to three. In another way, we can define the difference in cut-off value between the first membrane and the second membrane is between 20 000 and 30 000 daltons. The cut-off value of the first membrane might be less than or equal to 40 000 daltons, and the cut-off value of the second membrane might be less than or equal to 10 000 daltons. In one embodiment the cut-off value of the first membrane is approximately 40 000 daltons and the cut-off value of the second membrane is approximately 10 000 daltons.

To re-infuse water to the patient being treated, it is possible to connect to the output line 11 a post-dilution line 50 connected to a first source of sterile liquid 51 and (or) to the input line 10 a pre-dilution line 60 connected to a second source of sterile liquid 61.

A duct 40 makes a fluid connection between the first outlet 24 of the treatment unit 21 and the first inlet 2 of the exchanger 1.

The pre-dilution line 60 can be connected directly to said second duct 40 or directly to input line 10.

The different sources of sterile liquid 51, 61 can be bags of sterile liquid and (or) can be obtained by on-line preparation of sterile liquid from water drawn from a main supply system.

In the application of this invention to the special case of plasmapheresis, shown in Figures 9 and 10, the exchanger is a plasma filter. The plasma filter has a cut-off value between one million and five million daltons.

10 In this application, the exchanger or the treatment unit may comprise a hollow fiber membrane (also called capillary filter) or a plate membrane, this means with membrane sheets.

Thus the treatment unit 21 includes a unit able to fixate at least one given substance. This unit can be an adsorption cartridge, or a reactor, for example an electrophoresis cell.

The treatment unit can be equipped with a semi-permeable membrane 26 that divides it into a first chamber 27 with a first outlet 24 and a second chamber 28 with a first inlet 22 and a second outlet 25. The second outlet is connected to a discharge line. The treatment unit can have a cut-off value less than or equal 250 000 daltons.


The cut off value can be less than or equal to 200000 dalton.

20 The treatment unit can have a cut-off value such that 100% of the albumin molecules (with 58000 daltons as molecular weigh) can pass through the membrane.

Figure 9 shows a device comprising means to act on at least certain molecules 70. These means are connected to the first tube 12 between the second outlet 5 of the exchanger 1 and the first inlet 22 of the treatment unit 21. These means to act on at least certain molecules 70 can be a reactor, an adsorber or a radiation-based

9a

device, for example an electrophoresis, enzyme reaction, radiation, or ultraviolet irradiation device. The plasma filter can then have pores of one micron. The treatment unit can have a cut-off value less than or equal to 90 000 daltons, letting proteins through to the patient's blood.



Another feature of the invention is that it adds a third means of filtration to eliminate a further molecular mass range, shown in Figure 8. The device can comprise at least one auxiliary exchanger 81 with a membrane 86 that separates it in a first chamber 87 that is in fluid communication with a first inlet 82 and a first outlet 84 and in a second chamber 88 in fluid communication with at least one second outlet 85. The cut-off value of such an auxiliary exchanger will be less than the cut-off values of the other two membranes (6, 26).

10 The first inlet 82 of the auxiliary exchanger 81 is in fluid communication with the second outlet 24 of the treatment unit 21, and one of the two outlets 84 or 85 of the auxiliary exchanger 81 is in fluid communication with the first inlet 2 of the exchanger 1.

A second waste liquid discharge line 90 connects the other outlet 84, 85 of the auxiliary exchanger 81 to a drain, which drain can be a second waste liquid container 91.

Figure 8 shows the auxiliary exchanger operating in dialysis mode: the auxiliary exchanger 81 has a second inlet 83 in fluid communication with the second chamber 88 of the auxiliary exchanger 81 and in fluid communication with a third source of dialysis liquid 89, the first outlet 84 of the auxiliary exchanger 81 being in fluid communication with the first inlet 82 of the exchanger 1, the second outlet 85 of the auxiliary exchanger 81 being in fluid communication with a drain 91 via a second waste liquid discharge line 90.

20 The choice of the three membranes will be made very precisely according to the patient and the treatment required according to the molecular mass ranges that are to be eliminated or retained. The first membrane 6 is appropriate for molecules of high molecular mass (preferentially in haemo-filtration mode), the second membrane 26 is appropriate for molecules of mid-range molecular mass (preferentially in haemo-filtration mode), and the third membrane 86 is appropriate for molecules of low molecular mass, i.e., preferentially in dialysis mode. The auxiliary exchanger 81 can still operate in ultrafiltration mode if necessary. The choice of operating mode allows the treatment to be tailored to patient needs and to obtain optimal running with minimal clogging.

30 Concerning the regulation of the various fluid flow rates, first means for regulating active liquid flow rate 101 is placed on the input line 10 connected to the first inlet 2 of the exchanger 1. Alternatively, the first means to regulate flow rate (101) can be placed

exactly between the first inlet 2 of the exchanger 1 and the connection point 110 connecting the input line to the duct or upstream of the connecting point 110 connecting the input line 10 to the second duct 40.

In the first alternative, the pressure drop in the second duct 40 requires a lower positive pressure in the first duct 12 to reach the desired trans-membrane pressure (TMP) of the membrane 26.

Also, in the first alternative, it is not necessary to fit a pump on the second duct 40: a single pump 101 suffices for the second duct 40 and the arterial line 11.

10 In the second alternative, second means for regulating active liquid flow rate 102 is placed on the second duct 40 connecting the first outlet 24 of the treatment unit 21 to the first inlet 2 of the exchanger 1.

Third means for regulating active liquid flow rate 103 is placed on the first duct 12 connecting the second outlet 5 of the exchanger 1 to one of the inlets 22 or 23 of the treatment unit 21.

Also, fourth means for regulating active liquid flow rate 104 can be connected to the post-dilution line 50.

Fifth means for regulating active liquid flow rate 105 can be connected to the waste liquid discharge line 30 connecting the second outlet 25 of the treatment unit 21 to a drain 31.

20 In the configuration with at least three means of regulating flow rate 101 on the input line, 102 on the second duct 40 and 105 on the discharge line 30, special care must be taken to make sure the different flow rates set are compatible.

Sixth means for regulating active liquid flow rate 106 can be connected to the pre-dilution line 60.

The means for regulating flow rate 101, 102, 103, 104 and 105 can be pumps and (or) valves. In particular, the means for regulating flow rate on the discharge line 30, or on the post-dilution line 50 or the pre-dilution line 60 will be valves.

30 In a specific embodiment, the first post-dilution sterile liquid source 51 is a bag of sterile liquid and the first waste liquid container 31 connected to the discharge line leaving the treatment unit is a bag of waste liquid. The device comprises a first balance 120 to weigh the bag of sterile liquid 51 and a second balance 121 to weigh the bag of waste liquid 31. Alternatively, a single balance 120-121 can weigh the bag of sterile liquid 51 together with the bag of waste liquid 31.

In this case, a calculation and control unit 130 will receive the signals emitted by at least one balance 120-121 and will control the means for regulating liquid flow rate 101, 102, 103, 104 and 105.

The calculation and control unit periodically calculates the real flow rate or a parameter that is a function of the real flow rate, for example from the weight and the time interval between each two measurements. It will compare the real flow rate measured to the desired flow rate and will be able to control one or more means for regulating active liquid flow rate (101, 102, 103, 104, or 105).

10 Thus the quantities of sterile liquid and waste liquid, or their difference, can be monitored and controlled during the treatment. Knowing these weight quantities, the control unit can obtain a desired quantity of sterile liquid solution and waste liquid.

The hydric equilibrium can be well controlled in this way.

The device described above is applicable to plasmapheresis.

The invention also concerns a method for the extracorporeal treatment of blood to be implemented on a device for the extracorporeal treatment of blood comprising an exchanger 1 to which are connected a blood input line 10 and a blood output line 11, and a treatment unit 21, which method comprises the following steps:

- Sending blood through the input line 10 connected to the first inlet of the exchanger 1,
- 20 - Carrying out a first filtration of the blood in the exchanger 1, producing a first filtrate passing through the second outlet of the exchanger,
- Filtering the first filtrate at least a second time in the treatment unit 21, producing a second filtrate,
- Sending the second filtrate exiting the first outlet of the treatment unit to the input line 10 to effect a pre-dilution of the blood to be treated,
- Sending the blood out from the first outlet of the exchanger to the output line 11

In particular, the method will include a second filtration carried out through a semi-permeable membrane 26 in a treatment unit 21 divided into a first chamber 27 and a second chamber 28, yielding the second filtrate and sending the non-filtered liquid to the

30 drain line 30.

Another feature of the method is that the first filtration is carried out through a semi-permeable membrane 6 that divides the exchanger 1 into a first chamber 7 and a second chamber 8.

Another feature of the method is that the membrane 26 of the treatment unit filters molecules of molecular mass less than the molecular mass of the molecules filtered from the membrane 16 of the exchanger.

Another feature of the invention is that the method includes a step in which a sterile liquid is perfused in the blood output line 11 of the exchanger.

10 Another feature of the invention is that the method includes a step in which a sterile liquid is perfused in the blood input line 10 of the exchanger.

Another feature of the invention is that the method uses an exchanger membrane 16 with a cut-off value less than 40 000 dalton.

Another feature of the invention is that the method uses an exchanger membrane 16 with a cut-off value less than 10 000 dalton.

Another feature of the invention is that the treatment carried out is a plasmapheresis and the treatment unit fixates at least one certain given substance.


Another feature of the invention is that the exchanger membrane 16 has a cut-off value between one million and five million dalton.

20 Another feature of the invention is that the treatment unit membrane 16 has a cut-off value less than 250 000 dalton.

Simulations have been performed using filters with different cut-off values. Figures 10 and 11 show the estimated results in terms of clearance as a function of

13a

the molecular mass of solutes for two configurations of the device according to the invention. Figure 11 shows a first configuration using an exchanger with a cut-off value equal to 40 000 daltons, and a treatment unit using an exchanger with a cut-off value equal to 10 000 daltons. The clearance (curve 1) for molecules of about 11 000 daltons is very good, while



the clearance of small molecules is kept constant relative to an operating device equipped with a single filter (curve 2).

Figure 12 shows a second configuration for plasmapheresis using an exchanger with a cut-off value equal to 1 000 000 dalton, and a treatment unit using an exchanger with a cut-off value equal to 250 000 dalton. The clearance (curve 1') for molecules of about 300 000 dalton is very good, while the clearance of medium-sized molecules is kept constant relative to an operating device equipped with a single filter (curve 2').

The invention offers numerous advantages. It allows:

- 10 - A three- to fourfold increase in the clearance of medium-sized molecules (or large-sized molecules in plasmapheresis) relative to a standard long-term treatment, with no increase in the quantity of exchange liquid and with no change in the standard clearance of small-sized molecules (small- and medium-sized in plasmapheresis),
- Large savings in sterile liquid, and therefore lower operating costs,
- Sufficient elimination of medium-sized molecules,
- Retention of trace elements and nutrients, which are returned to the patient,
- High volume filtration.

20 In particular, in the configuration illustrated in Figure 5, many other advantages are offered. Minimal means of regulating flow rate are required: a peristaltic pump 101 on the arterial line and a pump 103 on the duct 40 are sufficient to operate the device.

Also, the positioning of the means for regulating flow rate is well conceived: there is not necessarily any need for a pump on the second duct 40, although one can still be fitted, and the means of regulating flow rate 103 need not be very powerful. This permits long-term operation for intensive care while avoiding heavy pore clogging of the various membranes.

Lastly, application of this operating scheme is envisaged for another mode of extracorporeal blood treatment, namely plasmapheresis. Plasmapheresis operation is optimal when the membranes are carefully chosen and used.

WHAT IS CLAIMED IS:

1. A device for the extracorporeal treatment of blood comprising:

- at least one exchanger (1) having a semi-permeable membrane (6) dividing said exchanger into a first chamber (7) and a second chamber (8), at least one first inlet (2) for blood to be treated in fluid communication with the first chamber (7), a first fluid outlet (4) in fluid communication with the first chamber (7) and a second fluid outlet (5) in fluid communication with the second chamber (8) of the exchanger (1),

10 - an input line (10) for blood to be treated connected to the first inlet (2) of the exchanger (1),

- a blood output line (11) connected to the first outlet (4) of the exchanger (1),

- at least one treatment unit (21) comprising a semi-permeable membrane (26), dividing the treatment unit (21) into a first chamber (27) and a second chamber (28), at least one first fluid inlet (22) in fluid communication with the second chamber (28), and at least one first fluid outlet (24) in fluid communication with the first chamber (27) of the treatment unit (21),

- the second outlet (5) of the exchanger (1) being in fluid communication with the first inlet (22) of the treatment unit (21),

20 - the first outlet (24) of the treatment unit (21) being in fluid communication with the input line (10),

wherein

- the treatment unit (21) includes a second fluid outlet (25) in fluid communication with the second chamber (28) of the treatment unit (21),

- the second outlet (25) of the treatment unit (21) is in fluid communication with a first waste liquid discharge line (30) having a first end and a second end, the first end of said first waste liquid discharge line being connected with the second

outlet (25) of the treatment unit (21) and the second end of said first waste liquid discharge being connected to a drain or to a first waste liquid container (31).

2. A device according to claim 1, wherein the exchanger (1) contains a semi-permeable membrane (6) dividing said exchanger into a first chamber (7) and a second chamber (8), the first inlet (2) of the exchanger is in fluid communication with the first chamber (7) of the exchanger, the first outlet (4) of the exchanger is in fluid communication with the first chamber (7) of the exchanger and the second outlet (5) of the exchanger is in fluid communication with the second chamber (8) of the exchanger.

10 3. A device according to claim 1 or 2, wherein the blood input line (10) connected to the first inlet (2) of the exchanger (1), the blood output line (11) connected to the first outlet (4) of the exchanger and the first chamber (7) of the exchanger form part of an extracorporeal blood treatment circuit.

4. A device according to any one of claims 1 to 3, wherein the exchanger (1) includes a second inlet (3) in fluid communication with the second chamber (8) and in fluid communication with a first source of dialysis liquid (9), the blood and the dialysis liquid circulating in opposite directions in each of the two chambers.

20 5. A device according to any one of claims 1 to 4, wherein the treatment unit (21) contains a semi-permeable membrane (26) dividing the treatment unit (21) into a first chamber (27) and a second chamber (28).

6. A device according to any one of claims 1 to 5, wherein the treatment unit (21) includes a second fluid outlet (25).

7. A device according to any one of claims 1 to 6, wherein:

- the first outlet (24) of the treatment unit (21) is in fluid communication with the first chamber (27) of the treatment unit (21), and

- the second outlet (25) of the treatment unit (21) is in fluid communication with the second chamber (28) of the treatment unit (21).

8. A device according to any one of claims 1 to 7, wherein the first inlet (22) of the treatment unit (21) is in fluid communication with the second chamber (28) of the treatment unit (21).

9. A device according to any one of claims 1 to 7, wherein the first inlet (22) of the treatment unit (21) is in fluid communication with the first chamber (27) of the treatment unit (21).

10. A device according to claim 1, wherein a first waste liquid discharge line (30) connects the second outlet (25) of the treatment unit (21) to a first waste liquid container (31).

11. A device according to any one of claims 1 to 10, wherein the treatment unit (21) includes a second inlet (23), which second inlet (23) is in fluid communication with the second chamber (28) and with a second source of dialysis liquid (29), which dialysis liquid flows in the opposite direction to the physiological liquid.

12. A device according to any one of claims 1 to 11, wherein a molecular permeability of the membrane (6) of the exchanger (1) is greater than a molecular permeability of the membrane (26) of the treatment unit (21), at least above a certain molecular weight.

20 13. A device according to any one of claims 1 to 12, wherein the membrane (6) of the exchanger (1) is a high-flow membrane and the membrane (26) of the treatment unit (21) is a low-flow membrane.

14. A device according to claim 12 or 13, wherein the difference in the cut-off value between said membrane (6) of the flow exchanger and said membrane (26) of the treatment unit lies between 20 000 daltons and 30 000 daltons.

15. A device according to any one of claims 12 to 14, wherein the cut-off value of the membrane (6) of the flow exchanger is less than or equal to 40 000 daltons.

16. A device according to any one of claims 12 to 15, wherein the cut-off value of the membrane (26) of the treatment unit is less than or equal to 10 000 daltons.

17. A device according to any one of claims 12 to 16, wherein the cut-off value of the membrane (6) of the flow exchanger is approximately 40 000 daltons.

10 18. A device according to any one of claims 12 to 17, wherein the cut-off value of the membrane (26) of the treatment unit is approximately 10 000 daltons.

19. A device according to any one of claims 1 to 18, wherein a post-dilution line (50) is connected to the output line (11) and is connected to a first source of sterile liquid (51).

20. A device according to any one of the claims 1 to 19, wherein a pre-dilution line (60) is in fluid communication with the input line (10) and connected to a second source of sterile liquid (61).

20 21. A device according to any one of claims 1 to 20, that includes a duct (40) to make a fluid communication between the first outlet (24) of the treatment unit (21) and the first inlet (2) of the exchanger (1).

22. A device according to claim 21, wherein the pre-dilution line (60) is connected directly to said duct (40).

23. A device according to claim 21, wherein the pre-dilution line (60) is connected directly to the input line (10).

24. A device according to any one of claims 19 to 23, wherein at least one source of sterile liquid (51, 61) is a bag of sterile liquid.

25. A device according to any one of claims 19 to 24, wherein at least one source of sterile liquid (51, 61) is obtained by an on-line preparation of sterile liquid using water taken from a mains supply.

26. A device according to any one of claims 1 to 25, wherein the exchanger is a plasma filter.

10 27. A device according to claim 26, wherein the plasma filter has a cut-off value between one million and five million daltons.

28. A device according to claim 26 or 27, wherein the treatment unit (21) comprises a unit able to fixate at least one given substance.

29. A device according to claim 28, wherein a unit able to pre-fixate at least one given substance is an adsorption cartridge.

30. A device according to claim 28, wherein the unit able to pre-fixate at least one given substance is a reactor.

31. A device according to claim 26 or 27, wherein the treatment unit contains a semi-permeable membrane (26):

20 - that divides the treatment unit (21) into a first chamber (27) with a first outlet (24) and a second chamber (28) with a first inlet (22) and a second outlet (25) connected to a discharge line, and

 - that has a cut-off value less than or equal to 250 000 daltons.

32. A device according to claim 31 that includes means to act on at least certain molecules (70) placed on the duct (12) between the second outlet (5) of the exchanger (1) and the first inlet (22) of the treatment unit (21).

33. A device according to claim 32, wherein the means to act on at least certain molecules is a reactor.

34. A device according to claim 32 or 33, wherein the means to act on at least certain molecules is a radiation device.

35. A device according to any one of claims 1 to 34, comprising at least one auxiliary exchanger (81) with a membrane (86) separating it into a first chamber (87) in fluid communication with a first inlet (82) and a first outlet (84) and a second chamber (88) in fluid communication with at least one second outlet (85), the cut-off value of which is lower than the cut-off values of the other two membranes (6, 26), wherein:

- the first inlet (82) of said auxiliary exchanger (81) is in fluid communication with the second outlet (24) of the treatment unit (21), and

- one of the two outlets (84 or 85) of the auxiliary exchanger (81) is in fluid communication with the first inlet (2) of the exchanger (1).

36. A device according to claim 35, wherein a second waste liquid discharge line (90) connects the other outlet (84 or 85) of the auxiliary exchanger (81) to a drain.

37. A device according to claim 36, wherein said drain is a second waste liquid container (91).

38. A device according to any one of claims from 35 to 37, wherein the auxiliary exchanger (81) has a second inlet (83) in fluid communication with the second chamber (88) of the auxiliary exchanger (81) and in fluid communication with a third source of dialysis liquid (89), and

- the first outlet (84) of the auxiliary exchanger (81) is in fluid communication with the first inlet (82) of the exchanger (1),

- the second outlet (85) of the auxiliary exchanger (81) is in fluid communication with a drain (91) via a second waste liquid discharge line (90).

39. A device according to any one of claims 1 to 38, wherein the first means to regulate active liquid flow rate (101) is placed on the input line (10) connected to the first inlet (2) of the exchanger (1).

40. A device according to claim 39, wherein the first means to regulate active liquid flow rate (101) placed on the input line (10) is placed exactly between the first inlet (2) of the exchanger (1) and the connection point (110) connecting the input line to the duct.

41. A device according to claim 39, wherein the first means to regulate active liquid flow rate (101) placed on the input line (10) is upstream of the connection point (110) connecting the input line (10) to the duct (40) and the second means to regulate active liquid flow rate (102) is placed on the duct (40) connecting the first outlet (24) of the treatment unit (21) to the first inlet (2) of the exchanger(1).

42. A device according to any one of claims 39 to 41, wherein third means to regulate active liquid flow rate (103) is placed on the duct (12) connecting the second outlet (5) of the exchanger (1) to one of the inlets (22, 23) of the treatment unit (21).

43. A device according to any one of claims 39 to 42, wherein fourth means to regulate active liquid flow rate (104) is placed on the post-dilution line (50).

44. A device according to any one of claims 39 to 43, wherein fifth means to regulate active liquid flow rate (105) is placed on the waste liquid discharge line (30) connecting the second outlet (25) of the treatment unit (21) to a drain (31).

45. A device according to any one of claims 39 to 44, wherein sixth means to regulate active liquid flow rate (106) is placed on the pre-dilution line (60).
46. A device according to any one of claims 43 to 45, wherein the first source (51) of sterile liquid for post-dilution is a bag of sterile liquid, and wherein the first waste liquid container (31) connected to the discharge line from the treatment unit is a bag of waste liquid.
47. A device according to claim 46, that includes a first balance (120) to weigh the bag of sterile liquid (51), and a second balance (121) to weigh the bag of waste liquid (31).
- 10 48. A device according to claim 46 that includes a single balance (120-121) to weigh the bag of sterile liquid (51) together with the bag of waste liquid (31).
49. A device according to claim 47 or 48 that includes a calculation and control unit (130) to receive signals emitted by at least one balance (120, 121) and to control the means to regulate active liquid flow rate (101, 102, 103, 104, or 105).

1/9




Fig. 1 – Prior art
Principle of reinjection in post-dilution




Fig. 2 – Prior art
Principle of reinjection in post-dilution

2/9




Fig. 3. — Prior art





Fig. 4 — Principle of the invention



4/9




Fig. 6 -- Exchanger in dialysis mode




Fig. 7 – Treatment unit in dialysis mode

6/9




Fig. 8 – Auxiliary exchanger
in dialysis mode

7/9




Fig. 9

Plasmapheresis

8/9




Fig. 10

9/9




Fig. 11

